A longitudinal study of changes in body mass index and total body composition after radioiodine treatment for thyrotoxicosis

被引:32
作者
DelaRosa, RE
Hennessey, JV
Tucci, JR
机构
[1] BROWN UNIV,SCH MED,PROVIDENCE,RI 02912
[2] RHODE ISL HOSP,DIV ENDOCRINOL & METAB,PROVIDENCE,RI
[3] ROGER WILLIAMS MED CTR,DIV ENDOCRINOL & METAB,PROVIDENCE,RI 02901
关键词
D O I
10.1089/thy.1997.7.401
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients treated for thyrotoxicosis often complain of increases in body weight after treatment of their thyroid disorder. The objective of this study was to define the extent of changes in body mass and composition following treatment of thyrotoxicosis with radioiodine I-131. We prospectively measured body mass index (BMT) in 75 patients (18 males, 57 females), ranging in age from 15-88 years heated for thyrotoxicosis with I-131 (doses ranging from 5.2 to 25.7 mCi) between 1978 and 1994. BMT pre- and post-radioiodine treatment were recorded for up to 10 years after treatment. Body composition studies were performed on a subgroup of 9 patients (1 male, 8 females), aged 24 to 74 years treated with 6.0 to 12.2 mCi I-131. Bone mineral content, lean mass, and fat content were determined prior to and following I-131 treatment through whole body scanning with a Hologic QDR-1000/W(R) dual energy x-ray densitometer. Sustained increases in BMI averaging 2.33 kg/m(2) above baseline (p<.01) were observed from the initial 6 months through the first 5 years after I-131 therapy. BMI was no different from pretreatment levels over the remainder of the 10-year follow-up period. Lean mass increased significantly (p=.0004) by an average of 7.2 kg. Although both fat and mineral content appeared to increase, these changes were not statistically significant. Weight gain occurs within the first year after I-131 treatment of patients with thyrotoxicosis and is predominantly due to increased lean mass (20.2%, p<.0005) although bone mineral content increased only marginally (4.62%, p=.10).
引用
收藏
页码:401 / 405
页数:5
相关论文
共 23 条
[1]  
ASP AA, 1993, 75 ANN M END SOC JCE
[2]  
BRAVERMAN LE, 1991, WERNER INGBARS THYRO, P645
[3]   EVALUATION OF OBESE PATIENT .1. ALGORITHM [J].
BRAY, GA ;
JORDAN, HA ;
SIMS, EAH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 235 (14) :1487-1491
[4]  
BRAY GA, 1976, JAMA-J AM MED ASSOC, V235, P2008
[5]   THE PAWTUCKET HEART HEALTH-PROGRAM - COMMUNITY CHANGES IN CARDIOVASCULAR RISK-FACTORS AND PROJECTED DISEASE RISK [J].
CARLETON, RA ;
LASATER, TM ;
ASSAF, AR ;
FELDMAN, HA ;
MCKINLAY, S .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (06) :777-785
[6]  
CROOKS J, 1959, Q J MED, V28, P211
[7]   THYROTOXIC BONE-DISEASE IN WOMEN - A POTENTIALLY REVERSIBLE DISORDER [J].
DIAMOND, T ;
VINE, J ;
SMART, R ;
BUTLER, P .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (01) :8-11
[8]   INFLUENCE OF CLINICAL CHARACTERISTICS AND PARAMETERS ASSOCIATED WITH THYROID-HORMONE THERAPY ON THE BONE-MINERAL DENSITY OF WOMEN TREATED WITH THYROID-HORMONE [J].
DUNCAN, WE ;
CHANG, A ;
SOLOMON, B ;
WARTOFSKY, L .
THYROID, 1994, 4 (02) :183-190
[9]   CHANGES IN BONE MASS DURING PROLONGED SUBCLINICAL HYPERTHYROIDISM DUE TO L-THYROXINE TREATMENT - A METAANALYSIS [J].
FABER, J ;
GALLOE, AM .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1994, 130 (04) :350-356
[10]   PROPRANOLOL, TRIIODOTHYRONINE, REVERSE TRIIODOTHYRONINE AND THYROID-DISEASE [J].
FEELY, J ;
ISLES, TE ;
RATCLIFFE, WA ;
CROOKS, J .
CLINICAL ENDOCRINOLOGY, 1979, 10 (05) :531-538